Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Double-dummy, Parallel Group, Multicenter Study of Once Daily Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, Twice Daily Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Twice Daily Fluticasone Propionate 250 mcg Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents Already Adequately Controlled on Twice-daily Inhaled Corticosteroid and Long-acting beta2 Agonist
Conditions
Interventions
Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler
Placebo inhalation powders via ELLIPTA inhaler
+3 more
Locations
179
United States
GSK Investigational Site
Huntington Beach, California, United States
GSK Investigational Site
Riverside, California, United States
GSK Investigational Site
Rolling Hills Estates, California, United States
GSK Investigational Site
San Diego, California, United States
GSK Investigational Site
Upland, California, United States
GSK Investigational Site
Denver, Colorado, United States
Start Date
March 1, 2015
Primary Completion Date
November 1, 2016
Completion Date
November 25, 2016
Last Updated
August 6, 2018
NCT06979323
NCT06664619
NCT07431021
NCT07383896
NCT07282886
NCT07356310
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions